Maze Therapeutics, Inc. Common Stock (NASDAQ:MAZE) — Stock Price
Maze Therapeutics, Inc. Common Stock (NASDAQ:MAZE) is currently trading at $27.28 USD, down 4.78% today. Over the past 52 weeks, shares have ranged between $13.23 and $51.84. This page tracks Maze Therapeutics, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Maze Therapeutics, Inc. Common Stock stock valuation.
Maze Therapeutics, Inc. Common Stock (MAZE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Maze Therapeutics, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Maze Therapeutics, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Maze Therapeutics, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $167.50 Million | $0.00 | $0.00 |
| Cost of Revenue | $2.40 Million | $3.30 Million | $4.09 Million | $3.82 Million |
| Gross Profit | $-2.40 Million | $167.50 Million | $-4.09 Million | $-3.82 Million |
| Research & Development | $108.45 Million | $83.50 Million | $73.94 Million | $88.19 Million |
| SG&A | $34.45 Million | $26.42 Million | $24.61 Million | $22.83 Million |
| Total Operating Expenses | $140.50 Million | $109.91 Million | $98.55 Million | $111.03 Million |
| Operating Income | $-142.90 Million | $57.59 Million | $-98.55 Million | $-111.03 Million |
| EBITDA | $-128.72 Million | $56.70 Million | $-96.33 Million | $-111.12 Million |
| EBIT | $-131.12 Million | $53.40 Million | $-100.42 Million | $-114.94 Million |
| Interest Expense | — | — | — | — |
| Income Before Tax | $-131.12 Million | $53.40 Million | $-100.42 Million | $-114.94 Million |
| Income Tax Expense | — | $1.17 Million | — | — |
| Net Income | $-131.12 Million | $52.23 Million | $-100.42 Million | $-114.94 Million |
Maze Therapeutics, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Maze Therapeutics, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $397.13 Million | $240.54 Million | $71.50 Million | $149.96 Million |
| Total Current Assets | $349.72 Million | $201.67 Million | $34.11 Million | $106.15 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | $152.67 Million | $0.00 | — | — |
| Net Receivables | $1.50 Million | — | — | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $42.16 Million | $43.64 Million | $61.45 Million | $48.51 Million |
| Total Current Liabilities | $22.56 Million | $20.67 Million | $16.32 Million | $20.78 Million |
| Long-term Debt | — | — | $20.08 Million | — |
| Net Debt | $-165.94 Million | $-170.18 Million | $20.46 Million | $-67.86 Million |
| Total Stockholder Equity | $354.97 Million | $196.90 Million | $10.05 Million | $101.44 Million |
| Retained Earnings | $-489.55 Million | $-358.43 Million | $-395.69 Million | $-295.27 Million |
Maze Therapeutics, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Maze Therapeutics, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-111.94 Million | $75.95 Million | $-86.83 Million | $-99.20 Million |
| Capital Expenditures | $794.00K | $1.15 Million | $441.00K | $1.97 Million |
| Free Cash Flow | $-112.73 Million | $74.81 Million | $-87.27 Million | $-101.17 Million |
| Investing Cash Flow | $-170.96 Million | $-1.15 Million | $-441.00K | $-3.17 Million |
| Financing Cash Flow | $275.34 Million | $92.85 Million | $16.39 Million | $1.73 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $16.40 Million | $9.65 Million | $8.75 Million | $6.74 Million |
| Depreciation | $2.40 Million | $3.30 Million | $4.09 Million | $3.82 Million |
| Change in Cash | $-7.57 Million | $167.65 Million | $-70.88 Million | $-100.64 Million |
Maze Therapeutics, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Maze Therapeutics, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 11, 2026 | — | -0.76 | — |
| May 13, 2026 | -0.45 | -0.62 | +27.75% |
| Mar 25, 2026 | -0.65 | -0.69 | +5.80% |
| Nov 06, 2025 | -0.66 | -0.69 | +4.35% |
| Aug 12, 2025 | -0.77 | -1.15 | +33.04% |
| May 14, 2025 | -1.15 | -0.63 | -82.54% |
| Mar 31, 2025 | -18.32 | 0.45 | -4171.11% |